Research
Microdosing: definition vs the evidence base
The GLP-1 weight-management evidence base is built on approved products at labeled doses — STEP for semaglutide, SURMOUNT for tirzepatide — none of wh
The GLP-1 weight-management evidence base is built on approved products at labeled doses — STEP for semaglutide, SURMOUNT for tirzepatide — none of which studied a deliberate 'microdose.' So 'microdosing' is a commercial term describing a practice the randomized literature has not evaluated. Compounded products are not FDA approved.
What the trials establish
This page anchors the whole research cluster: it separates what is proven (approved products at studied doses) from what is marketed (below-label 'microdosing'). The pivotal trials — STEP 1 (~14.9% weight loss) and SURMOUNT-1 (~20.9%) — enrolled thousands of participants and used the labeled maintenance doses, not fractions of them.
No randomized controlled trial has tested a deliberate microdose for weight management. That is not a subtle gap; it is the central one. Every downstream claim about microdose efficacy is an extrapolation from studied doses, and extrapolation is not evidence.
The withdrawal trials (STEP 4, SURMOUNT-4) add the maintenance dimension: stopping leads to regain, which is why duration — and therefore cost — matters. These are the four load-bearing trials for anyone reasoning honestly about GLP-1 microdosing.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| STEP 1 | Adults with overweight/obesity, without diabetes | 1,961 | Mean weight change about -14.9% vs -2.4% placebo | Wilding JPH, et al. N Engl J Med 2021;384:989-1002 | NCT03548935 · PMID 33567185 · DOI |
| STEP 4 | Adults with overweight/obesity after 20-week run-in | 803 | Continuing lost further weight; switching to placebo regained substantial weight | Rubino D, et al. JAMA 2021;325(14):1414-1425 | NCT03548987 · PMID 33755728 · DOI |
| SURMOUNT-1 | Adults with obesity, without diabetes | 2,539 | Up to about -20.9% at 15 mg vs -3.1% placebo | Jastreboff AM, et al. N Engl J Med 2022;387(3):205-216 | NCT04184622 · PMID 35658024 · DOI |
| SURMOUNT-4 | Adults with obesity after lead-in | 670 | Continued treatment maintained loss; withdrawal led to regain | Aronne LJ, et al. JAMA 2024;331(1):38-48 | NCT04660643 · PMID 38078870 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Is there research on GLP-1 microdosing?
No randomized trial has tested a deliberate microdose. The evidence is for approved products at labeled doses.
What are the key trials?
STEP 1 and SURMOUNT-1 for weight loss; STEP 4 and SURMOUNT-4 for maintenance/withdrawal.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.